Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Depreciation and Depletion (2016 - 2024)

Perspective Therapeutics (CATX) has disclosed Depreciation and Depletion for 11 consecutive years, with -$1.6 million as the latest value for Q4 2024.

  • Quarterly Depreciation and Depletion fell 131.73% to -$1.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$1.6 million through Sep 2025, down 275.92% year-over-year, with the annual reading at $267000.0 for FY2022, N/A changed from the prior year.
  • Depreciation and Depletion hit -$1.6 million in Q4 2024 for Perspective Therapeutics, down from $669000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $669000.0 in Q3 2024 to a low of -$1.6 million in Q4 2024.
  • Historically, Depreciation and Depletion has averaged $29315.8 across 5 years, with a median of $64000.0 in 2022.
  • Biggest YoY gain for Depreciation and Depletion was 280.88% in 2023; the steepest drop was 595.65% in 2023.
  • Year by year, Depreciation and Depletion stood at $37000.0 in 2020, then plummeted by 310.81% to -$78000.0 in 2021, then soared by 276.92% to $138000.0 in 2022, then plummeted by 595.65% to -$684000.0 in 2023, then tumbled by 131.73% to -$1.6 million in 2024.
  • Business Quant data shows Depreciation and Depletion for CATX at -$1.6 million in Q4 2024, $669000.0 in Q3 2024, and $570000.0 in Q2 2024.